A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.

Name: A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.
License: Public Domain

Fondazione Ricerca Traslazionale

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

nsclc

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 200216
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.